Dyne Therapeutics to Announce Phase 1/2 Trial Results on December 8, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 11 hour ago0mins
- Clinical Results Announcement: Dyne Therapeutics plans to release topline clinical results from the Registrational Expansion Cohort of the Phase 1/2 DELIVER trial on December 8, 2025, which is expected to positively impact the company's market positioning in genetically driven neuromuscular diseases.
- Webcast Arrangement: The company will host a webcast at 8:00 a.m. ET, providing detailed clinical data that could enhance investor confidence in its R&D progress and potentially attract more investment.
- Long-term Development Strategy: Dyne focuses on developing therapeutics targeting muscle and the central nervous system to address the root causes of diseases, positioning itself for significant market presence in the future.
- Diverse Pipeline: The company is advancing clinical programs for myotonic dystrophy and Duchenne muscular dystrophy while also conducting preclinical research for facioscapulohumeral muscular dystrophy and Pompe disease, demonstrating its extensive commitment to the neuromuscular disease sector.
DYN.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 34.90 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 20.650
Low
11.00
Averages
34.90
High
48.00
Current: 20.650
Low
11.00
Averages
34.90
High
48.00
Bernstein
Market Perform
maintain
$12 -> $21
2025-11-25
Reason
Bernstein
Price Target
$12 -> $21
2025-11-25
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Dyne Therapeutics to $21 from $12 and keeps a Market Perform rating on the shares. The firm sees Dyne's risk-reward as favorable even following the recent move. Next catalyst is for DYN-251 in Duchenne Muscular Dystrophy with data for the registrational expansion cohort.
JPMorgan
Neutral
downgrade
$18 -> $17
2025-11-14
Reason
JPMorgan
Price Target
$18 -> $17
2025-11-14
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Dyne Therapeutics to $17 from $18 and keeps a Neutral rating on the shares. The firm updated the company's model.
Oppenheimer
Andreas Argyrides
Perform
downgrade
$13 -> $11
2025-11-12
Reason
Oppenheimer
Andreas Argyrides
Price Target
$13 -> $11
2025-11-12
downgrade
Perform
Reason
Oppenheimer analyst Andreas Argyrides lowered the firm's price target on Dyne Therapeutics (DYN) to $11 from $13 and keeps a Perform rating on the shares following quarterly results and business update. The firm continues to see upcoming Phase 1/2 DELIVER expansion cohort data for DYNE-251/DMD in December 2025 as an important clearing event, supporting a potential BLA submission for accelerated approval in Q2 2026. In October, Novartis (NVS) announced the acquisition of competitor Avidity. While the deal broadly provided positive readthrough to antisense oligonucleotides for rare diseases, the firm sees the deal reinforcing its thesis that Dyne's programs require further derisking on safety before assigning additional value.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$38 -> $46
2025-11-06
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$38 -> $46
2025-11-06
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Dyne Therapeutics to $46 from $38 and keeps a Buy rating on the shares. The firm believes Dyne's dual Breakthrough programs in myotonic dystrophy and Duchenne muscular dystrophy are now entering registrational stages with "validated functional and biomarker data. This positions the company for clinical catalysts and as a strategic takeover asset, the analyst tells investors in a research note. The Avidity acquisition "sets a clear benchmark, and Dyne's more mature dataset strengthens the case for a higher premium takeout," contends H.C. Wainwright.
See All Ratings
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why did Clene Inc.'s shares rise after hours despite earlier decline?
What factors contributed to Werewolf Therapeutics' 6.12% after-hours stock increase?
Will Clene Inc.'s upcoming ALS update further boost its stock performance?
Could Biomea Fusion's icovamenib presentation lead to sustained stock growth?